ライフサイエンスコーパス: factor H

1 ils compared with the major allele (Val62 in factor H).

2 in on PGA formation are tightly regulated by Factor H.

3 ivation in individuals with fully functional factor H.

4 n tissues suppresses regulation of the AP by factor H.

5 Lchain restriction during reactivity against factor H.

6 ent cascade by interacting with C1q and with Factor H.

7 d to more potent inhibition of complement by factor H.

8 ment cascade C1q, C6, and C8; and complement factor H.

9 s, such as C-reactive protein and complement factor H.

10 e five FHR proteins with each other and with Factor H.

11 inding of inhibitors C4b-binding protein and factor H.

12 llular matrix, recruited functionally active factor H.

13 (fHbp), a lipoprotein able to bind the human factor H.

14 rocolitica and Y. pseudotuberculosis recruit factor H.

15 own to bind the complement regulator protein factor H.

16 Hic differs from binding to vitronectin and factor H.

17 nt receptor 1 but did not perturb binding to factor H.

18 l anisotropy was largely due to nonheritable factors (h(2) = 0.185, p = .077).

19 we consider moss-produced recombinant human factor H a promising pharmaceutical product for therapeu

20 n African trypanosome receptor for mammalian factor H, a negative regulator of the alternative pathwa

21 Unlike factor H, a potent negative regulator of complement C3 a

22 Ten loci in 7 AMD genes [complement factor H, age-related maculopathy susceptibility 2/high-

23 In contrast to C3b or Factor H alone, the solubility of the central C3b-Factor

24 osporine-induced microparticles did not bind factor H, an alternative pathway regulatory protein pres

25 In this study, we sequenced two maternal (factor H and C3) and one fetal (CD46) complement genes a

26 ut affected binding of complement inhibitors factor H and C4b-binding protein.

27 or the interaction of Y. pestis Ail with Vn, factor H and C4BP.

28 ctions of the negative complement regulators Factor H and complement receptor 1 with C3b.

29 t regulatory factors C4b-binding protein and factor H and confirmed that the ability to bind at least

30 in A (sIgA) but not the complement regulator factor H and did not decrease C3b deposition on the pneu

31 y activity similar to that of plasma-derived factor H and efficiently blocked LPS-induced alternative

32 product that lacks the recognition domain of factor H and exhibits impaired cell surface complement r

33 ans uses human complement regulators such as factor H and factor H-like protein 1 (FHL-1) for immune

34 annexin A2 impaired complement regulation by factor H and increased complement activation on renal ce

35 tion of C3b only occurred with the cofactors factor H and soluble CR1 but not with CD46.

36 context, the balance between the actions of factor H and the FHR proteins determines the degree of c

37 In mice deficient in complement factor H and transgenic for human CR1, soluble CR1 thera

38 gous to the complement inhibitory domains of factor H and, accordingly, has no significant complement

39 y in aged (12 months) mice deficient in both factors H and C3 (CFH(-/-).C3(-/-)), CFH alone (CFH(-/-)

40 n the presence of the complement regulators (factors H and I), and this degradation results in lower

41 tio; the C3b portion was rapidly degraded by factors H and I.

42 ous regulation of C3b deposition mediated by Factors H and I.

43 ies on the interaction of C3b with Factor B, Factor H, and complement receptor 1.

44 the alternative pathway negative regulator, Factor H, and how aiming to understand these interaction

45 Patients with MPGN had normal levels of factor H, and structural analysis of the mutant revealed

46 or simultaneous interaction with both Vn and factor H, and that it recognized the C-terminal part of

47 tic complement abnormalities/anti-complement factor H antibodies, which paved the way to treatment wi

48 Mutations and genetic variations of factor H are associated with several AP-mediated disease

49 genes CFHR1, CFHR2, CFHR3, CFHR4, CFHR5, and Factor H are linked to the human kidney diseases atypica

50 les of the factor H-related proteins, unlike factor H, are incompletely understood.

51 l surface protein, possesses vitronectin and factor H binding activity.

52 thin outer membrane P5 affected the level of factor H binding between individual strains.

53 spectrometry, we identified annexin A2 as a factor H binding partner.

54 st sheaths presenting Neisseria meningitidis factor H binding protein (fHbp) antigen were functional

55 is not known to bind human FH, and a mutant factor H binding protein (FHbp) antigen with a >50-fold

56 isolates, we identified four (16%) with high factor H binding protein (FHbp) expression that were res

57 Factor H binding protein (fHbp) is a lipoprotein of Neis

58 Factor H binding protein (FHbp) is an important Neisseri

59 Factor H binding protein (FHbp) is part of two vaccines

60 iques, we generated a series of mAbs against factor H binding protein (fHbp), a key virulence factor

61 oteins, including the Neisseria meningitidis factor H binding protein (fHbp), a lipoprotein able to b

62 Factor H binding protein (fHbp), a virulence factor whic

63 ride, lipooligosaccharide (LOS) sialic acid, factor H binding protein (fHbp), and neisserial surface

64 which also remove desirable antigens such as factor H binding protein (FHbp).

65 icensed; both vaccines contain meningococcal factor H binding protein (fHbp).

66 3 recombinant antigens (Neisseria adhesin A, factor H binding protein [fHbp]-GNA2091, and Neisserial

67 Cocrystal structure of meningococcal factor H binding protein variant 3 reveals a new crosspr

68 test strains expressing vaccine-heterologous factor H binding protein variants: PMB80 (A22), PMB2001

69 MenB-FHbp (factor H binding protein), a serogroup B meningococcal (

70 for capsule biosynthesis, the expression of factor H binding protein, and sialylation of lipopolysac

71 Bivalent rLP2086 is a recombinant factor H binding protein-based vaccine approved in the U

72 examined both proteins in animal infection, factor H binding, and serum sensitivity assays.

73 d complement resistance through varied human factor H binding, that may affect invasiveness in childr

74 monoclonal antibodies (mAbs) raised against factor H-binding protein (fHbp) and Neisserial Heparin-B

75 on of the pharyngeal swabs (78.3%) yielded a Factor H-Binding Protein (fHbp) nucleotide allele sugges

76 cocci to express similar amounts of the same factor H-binding protein (fHbp; a key component of group

77 ere closely related to the vaccine antigens (factor H-binding protein [fHbp] and neisserial heparin-b

78 ty of the nitrite reductase gene (aniA), the factor H-binding protein gene (fHbp), and the capsule bi

79 a licensed meningococcal B vaccine targeting factor H-binding protein.

80 strains that expressed vaccine-heterologous factor H-binding proteins representative of meningococca

81 We conclude that factor H binds to VWF and may modulate cleavage of VWF b

82 We found that factor H binds to VWF in plasma, to plasma-purified VWF,

83 d analysis showed that FHR3, but not FHR1 or factor H, blocked B cell activation by the BCR corecepto

84 solate, and reported that Hif interacts with factor H by expressing protein H (PH).

85 nt of complement regulatory factors, such as factor H, C4b-binding protein (C4BP) and vitronectin (Vn

86 enetic risk was based on Y402H in complement factor H (CFH) and A69S in age-related maculopathy susce

87 lymorphisms were genotyped in the complement factor H (CFH) and ARMS2 genes using a Taqman assay.

88 r at chromosome 1q32 contains the complement factor H (CFH) and five complement factor H-related (CFH

89 ious complement factors including complement factor H (CFH) and to promote the removal of both subend

90 Mice deficient in complement factor H (CFH) are a classic C3G model, with kidney dise

91 nd genetic variants in inhibitory complement factor H (CFH) are also features of both ARMD and TMA, w

92 /-) or a heterozygous mutation of complement factor H (cfh) at amino acid residue of 1206 (ie, cfh (W

93 Genetic variations in complement factor H (CFH) confer greater risk for age-related macul

94 Rare variants in the complement factor H (CFH) gene and their association with age-relat

95 le why non-coding variants in the complement factor H (CFH) gene are more strongly associated with ag

96 ocus on genetic variations in the complement Factor H (CFH) gene cluster and CFH autoantibodies in si

97 of the Y402H risk variant in the complement factor H (CFH) gene developed neovascular AMD 2.8 (95% C

98 t amino acid position 402) in the complement factor H (CFH) gene have a pharmacogenetics effect on th

99 chromosome 1q31.1 containing the complement factor H (CFH) gene was strongly associated with serum M

100 Sanger sequencing analysis of the complement factor H (CFH) gene.

101 athy susceptibility 2 (ARMS2) and complement factor H (CFH) genotypes, and other factors, mean IMT wa

102 Complement factor H (CFH) is a major susceptibility gene for age-re

103 Complement factor H (CFH) is a negative regulator of the alternativ

104 Complement factor H (CFH) is an important regulatory protein in the

105 62V substitutions in the gene for complement factor H (CFH) is strongly associated with risk of AMD.

106 loci and 6 additional SNPs at the complement factor H (CFH) locus.

107 tion is efficiently suppressed by complement factor H (CFH) on self-surfaces but not on foreign surfa

108 d presence of risk alleles of the complement factor H (CFH) or age-related maculopathy susceptibility

109 Complement factor H (CFH) regulates complement activation in host t

110 .1 years, individuals with 1 or 2 complement factor H (CFH) risk alleles derived maximum benefit from

111 and AMD-susceptibility genotypes Complement Factor H (CFH) RS1061170 and Age Related Maculopathy Sus

112 Two loci in complement factor H (CFH) were included in a risk score to determin

113 d their possible interaction with Complement Factor H (CFH) Y402H and Complement factor 3 (C3) rs2230

114 us (CMV) immunoglobulin (Ig)G and complement factor H (CFH) Y402H genotype.

115 Molecular defects in complement factor H (CFH), a critical regulatory protein of the com

116 Genetic variants within complement factor H (CFH), a major alternative complement pathway r

117 These include complement factor H (CFH), a negative regulator of C3 activation.

118 Ten genetic loci in 7 genes [complement factor H (CFH), age-related maculopathy susceptibility 2

119 filtered for rare variants in the complement factor H (CFH), complement factor I (CFI), complement C9

120 ysiological complement inhibitor, complement factor H (CFH), for ligand binding.

121 ariants of the CFH gene, encoding complement factor H (CFH), show strong association with age-related

122 the protective genetic alleles of complement factor H (CFH), the Mediterranean diet had further benef

123 the negative complement regulator complement factor H (CFH), thereby inhibiting the alternative pathw

124 ijacking a host-immune regulator, complement factor H (CFH), to the bacterial surface.

125 comparison of hemopexin (HPX) and complement factor H (CFH), two liver-secreted glycoproteins, in hea

126 , smoking status, presence of the complement factor H (CFH)-rs1061170 and age-related maculopathy sus

127 and rare, in the coding region of complement factor H (CFH).

128 roteins or autoantibodies against complement factor H (CFH).

129 athy susceptibility 2 (ARMS2) and complement factor H (CFH).

130 four retinal genes interact with Complement Factor H (CFH).

131 ted macular degeneration (AMD) is complement factor H (CFH); however, its impact on AMD pathobiology

132 hromosome 1q31.3 encompassing the complement factor H (CFH, FH) and CFH related genes (CFHR1-5) are m

133 ecific for the central complement regulator, factor H, combined with a homozygous deficiency, mostly

134 The removal of the C3b-Factor H complex by zinc explains the reduced C3u/C3b in

135 u(1032) salt bridge is essential for the C3b-Factor H complex during the regulatory control of C3b, t

136 r H alone, the solubility of the central C3b-Factor H complex was much reduced at 60 muM zinc and eve

137 Substitution with biologically active factor H could potentially treat a variety of diseases t

138 , C. albicans cell extract was absorbed to a factor H-coupled matrix.

139 or showed a nonsense CFH mutation leading to factor H deficiency.

140 y decreased in the absence of either OlpA or factor H, demonstrating that this inhibition of the alte

141 nd there was a differential binding of human factor H, depending on invasiveness.

142 f an improved moss-derived recombinant human factor H devoid of potentially immunogenic plant-specifi

143 to bind human complement regulatory protein factor H directly, thereby, preventing complement factor

144 Factor H enhanced ADAMTS-13-mediated cleavage of recombi

145 DAF) expression on endothelial cells, giving Factor H (FH) a major role in complement regulation.

146 Factor H (FH) and C4-binding protein (C4BP), which conco

147 Gonococci bind the complement inhibitors factor H (FH) and C4b-binding protein (C4BP) in a human-

148 The plasma proteins Factor H (FH) and its alternate splice variant FH-like p

149 Factor H (fH) and properdin both modulate complement; ho

150 nomic disorders affecting the genes encoding factor H (fH) and the 5 factor H related proteins have b

151 mic aberrations affecting the genes encoding factor H (FH) and the five FH-related proteins (FHRs) ha

152 after intraperitoneal administration of anti-Factor H (FH) antibodies or isotype control.

153 nition domains 19-20 of complement regulator factor H (FH) are strongly associated with aHUS, but the

154 s to be efficiently down-regulated by plasma factor H (FH) as exemplified by various diseases caused

155 Factor H (fH) binding protein (fHbp) is part of vaccines

156 Further, we show that complement factor H (FH) binds mCRP to dampen its proinflammatory a

157 Complement regulatory protein factor H (fH) binds modified host proteins and lipids to

158 the complement alternative pathway regulator factor H (FH) competes with factor B for C3b binding; ho

159 binding of the alternative pathway inhibitor factor H (FH) could be one mechanism causing variations

160 nt inhibitors C4b-binding protein (C4BP) and factor H (FH) exert a tight regulation of the classical/

161 controlled by regulatory proteins, including factor H (FH) in plasma and membrane cofactor protein (M

162 3dg and enhanced competition with complement factor H (FH) in surface plasmon resonance (SPR) studies

163 Complement factor H (FH) inhibits complement activation and interac

164 Factor H (FH) is a key alternative pathway regulator tha

165 Complement factor H (fH) is a plasma protein that regulates activat

166 Factor H (fH) is an endogenous negative regulator of the

167 Factor H (FH) is the most important fluid-phase regulato

168 The plasma complement regulator factor H (FH) is thought to be the main regulator that p

169 The complement factor H (FH) mutation R1210C, which was described in as

170 his because it recruits complement regulator factor H (FH) onto the bacterial surface to evade comple

171 (Y402H), within the gene encoding complement factor H (FH) predisposes individuals to acquiring age-r

172 binding of the alternative pathway regulator factor H (fH) to PorB of some strains.

173 ty by binding the human complement regulator factor H (fH) with high affinity, is also a key antigen

174 s complement-mediated destruction by binding factor H (FH), a host-derived negative regulator of comp

175 sms, mutations, and autoantibodies affecting factor H (FH), a major regulator of the alternative comp

176 P5 expression was required for NT127 to bind factor H (fH), an important inhibitor of alternative pat

177 The serum proteins factor H (FH), consisting of 20 complement control prote

178 Serum concentrations of factor H (FH), factor I (FI), C9, and C3 were measured,

179 associated with polymorphisms of complement factor H (FH), implicating immune vulnerability.

180 their interaction with the control proteins factor H (FH), membrane cofactor protein (MCP; CD46), an

181 structurally related to complement inhibitor factor H (FH), the initial assumption was that the FHRs

182 ate complement system, many microbes capture factor H (FH), the key soluble complement-regulating pro

183 enzae lipoprotein having the ability to bind factor H (FH), the major regulator of the alternative pa

184 he proteolytically activated form of C3, and factor H (FH), the surface-sensing C3b-binding complemen

185 e physiological plasma complement regulator, factor H (FH), we studied the effect of Ecb on the compl

186 One such host regulator is factor H (FH), which acts as a negative regulator of com

187 Autoantibodies targeting factor H (FH), which is a main alternative complement pa

188 catalyzed by factor I (FI) and its cofactor, factor H (FH), with or without the participation of huma

189 ructural insight on the complement regulator factor H (FH), yielding a novel complement-targeted ther

190 The meningococcal vaccine antigen, factor H (FH)-binding protein (FHbp), binds human comple

191 s functional defects in complement regulator factor H (FH).

192 tions in the inhibitory complement regulator factor H (FH).

193 r of the AP is the plasma protein complement factor H (FH).

194 pathway activity is inhibited by complement factor H (FH).

195 ein contributes to immune evasion by binding factor H (FH).

196 -specific ligand of the complement inhibitor factor H (FH).

197 nd factor (VWF) and the complement regulator factor H (FH).

198 d the inhibitory domain of the CAP regulator factor H (fH).

199 tein (MCP; CD46), but a normal regulation by factor H (FH).

200 of the alternative complement pathway, human factor H (FH).

201 ncluding binding of the complement inhibitor factor H (FH).

202 in Bruch's membrane (BrM) of the macula, and factor H (FH).

203 rotein that binds to a complement regulator, factor H (FH).

204 converting the FHR-1 C terminus into that of factor H (FH).

205 We analyzed the efficiency of factor H (FH)6-7/Fc, a novel antibacterial immunotherape

206 enhances complement resistance by recruiting factor H (FH; alternative complement pathway inhibitor)

207 cleotide polymorphisms and rare mutations in factor H (FH; official name, CFH) are associated with ag

208 , Factor H::FHR hybrid proteins, and altered Factor H, FHR plasma profiles cause pathology is of high

209 rstanding how mutant or hybrid FHR proteins, Factor H::FHR hybrid proteins, and altered Factor H, FHR

210 ); between rs2669845 and Y402H in complement factor H for AMD (P = .04); and between rs2669845, rs285

211 Factor H forms large oligomers in >10 muM zinc.

212 binds ligand, leaving inhibitory domains of factor H free to inactivate complement C3b deposited on

213 This suggests that factor H function is affected by local conditions within

214 platelets became complement susceptible when factor H function was blocked.

215 ted tissue inflammation by locally impairing factor H function, but it can also improve complement-me

216 logic outcome is emerging: CFHR1, CFHR3, and Factor H gene alterations combined with intact CFHR2, CF

217 five CFHR genes in the context of an intact Factor H gene are described in C3 glomerulopathy.

218 and copy number variations in the human CFHR-Factor H gene cluster comprising the complement genes CF

219 s 358 kb region that contains the Complement Factor H gene cluster.

220 s have found variation within the complement factor H gene family links to host susceptibility to men

221 and the Y402H polymorphism in the complement factor H gene on chromosome 1q) and mortality.

222 or mutant CFHR genes, as well as hybrid CFHR-Factor H genes, and alter the FHR and Factor H plasma re

223 Complement factor H genotype had no effect on the responses to pazo

224 Deficiency of complement factor H has long been associated with MPGN.

225 diseases, highlighting the critical role of factor H in AP regulation.

226 ed the expression of full-length recombinant factor H in moss (Physcomitrella patens).

227 gial immunodeposits, including properdin and factor H in the alternative pathway and mannan-binding l

228 the corresponding gene products compete with factor H in the regulation of the alternative pathway, i

229 beta peptide 1-42, C4b-binding protein, and factor H, in a CRP concentration- and ligand concentrati

230 Factor H is a circulating protein that regulates activat

231 Although factor H is a well known inhibitor of the alternative co

232 Factor H is an important complement regulator of the alt

233 ative pathway activation, but no therapeutic factor H is commercially available.

234 s 1q31.3, containing the gene for complement factor H (lead single nucleotide polymorphism: rs800292;

235 ently cleaved by factor I in the presence of factor H, leading to enhanced C3 fragment deposition on

236 carriers of rs800292 minor allele (Ile62 in factor H) led to decreased release of MMP-8 from neutrop

237 Carriers tended to have low serum Factor H levels, especially carriers of the splice varia

238 host iron availability and higher complement factor H levels, lower expression of gametocyte-associat

239 Mutant recombinant factor H like-1 (FHL-1) proteins were expressed in HEK29

240 n complement regulators such as factor H and factor H-like protein 1 (FHL-1) for immune evasion.

241 reduced binding of CFH or its splice variant factor H-like protein 1 (FHL-1) to self-ligands or alter

242 Here we report that factor H-like protein 1 (FHL-1), which contains FH domai

243 Inhibition of factor H-mediated cell surface complement regulation sig

244 ein stabilized the C3 convertase and reduced factor H-mediated convertase decay.

245 Addition of factor H mitigates the complement attack.

246 on causing aHUS, including 4 with complement factor H mutations.

247 A small fraction of C3G-DDD cases linked to factor H or C3 gene mutations as well as autoantibodies

248 however, neither OMP was found to bind human factor H or to be required for enhancing serum resistanc

249 proximately 1 mg purified moss-derived human factor H per liter of initial P. patens culture after a

250 d CFHR-Factor H genes, and alter the FHR and Factor H plasma repertoire.

251 the human complement regulators factor I and factor H, promoting inactivation of C3b.

252 val of Crry/DAF-deficient platelets aided by factor H protection and compensatory thrombopoiesis demo

253 The complement factor H R1210C rare variant confers the strongest genet

254 The typical phenotype of the complement factor H R1210C rare variant is associated with extensiv

255 a novel heterozygous mutation in complement factor H (R83S) in addition to known risk polymorphisms

256 Furthermore, injection of moss-derived factor H reduced C3 deposition and increased serum C3 le

257 ying a genetic abnormality in the complement factor H related 1 gene (CFHR1) that originates by recur

258 g the genes encoding factor H (fH) and the 5 factor H related proteins have been described in associa

259 We demonstrate that complement factor-H related 3 (CFHR3) promotes immune activation by

260 Copy number variations in the complement factor H-related (CFHR) gene cluster on chromosome 1q32

261 ied a chromosomal deletion in the complement factor H-related (CFHR) gene cluster.

262 mmune renal disease deficient for complement factor H-related (CFHR) genes and autoantibody-positive

263 omplement factor H (CFH) and five complement factor H-related (CFHR) genes.

264 genomic rearrangements within the complement factor H-related (CFHR) locus.

265 The role of the complement factor H-related (FHR) proteins in homeostasis, pathogen

266 ated genomic mutation in the gene complement factor H-related 1 (CFHR1), which encodes FHR1.

267 hat a duplication within the gene complement factor H-related 1 (CFHR1; encoding FHR1) leads to the p

268 The human complement Factor H-related 5 protein (FHR5) antagonizes the main c

269 udies have shown that deletion of complement factor H-related genes 1 and 3 (CFHR3,1Delta) is associa

270 on studies identified deletion of complement factor H-related genes 1 and 3 as protective against the

271 Factor H-related protein (FHR) 1 is one of the five huma

272 ociation of rs7517126 with plasma complement factor H-related protein 1 (CFHR1) level at p<1.46x10(-6

273 nous nitric oxide production) and complement factor H-related protein 2 (CFHR2, related to complement

274 Complement factor H-related proteins (FHRs) are strongly associated

275 locus is complex and biological roles of the factor H-related proteins, unlike factor H, are incomple

276 est decreased inhibition of C3 by complement factor H, resulting in increased activation of the alter

277 es the main circulating complement regulator Factor H, resulting in the deregulation of complement ac

278 Interactions with complement factor H (rs1061170), age-related maculopathy susceptibi

279 This glycosylation-optimized factor H showed full in vitro complement regulatory acti

280 These genes include the sigma factor H (sigH) that was shown to be important for M. av

281 The role of complement factor H still needs to be better defined, but in light

282 Ail weakly recruits Vn and fails to recruit factor H, suggesting that this alternative mechanism of

283 diseases affect the glycoprotein complement factor H, the main regulator of the alternative pathway

284 howed that annexin A2 reduces the binding of factor H to cell surfaces.

285 C3b, then C3b is inactivated by Factor I and Factor H to form the C3c and C3d fragments.

286 We used purified murine factor H to immunoprecipitate binding partners from mous

287 hat inducible proteins impair the ability of factor H to locally control the AP, thereby increasing A

288 nt of the complement downregulators C4BP and factor H to the pneumococcal cell wall and directly clea

289 his study, we show that M. catarrhalis binds factor H via the outer membrane protein OlpA.

290 stic of sub-RPE deposits, such as complement factor H, vitronectin, and amyloid beta, revealed that H

291 otein and positively with afamin, complement factor H, VLDL-associated apolipoproteins, and lipid sub

292 Binding of mutant C3 to factor H was normal, but mutant C3 was less efficiently

293 L-6), interleukin-10 (IL-10), and complement factor H was unaffected.

294 vating protein, factor B, and the inhibitor, factor H, which are opposite effects that complicate its

295 ptors, IgM natural antibodies and complement factor H, which bind, neutralize and/or facilitate their

296 In contrast, Factor H, which binds to the N-terminal part of mature P

297 so had decreased binding of human complement Factor H, which in previous studies increased the protec

298 he FHR3 binding sites on C3d are occupied by factor H, which lacks B cell-inhibitory functions.

299 as even more compact than the main regulator Factor H, which showed an overall length of 26-29 nm for

300 y Susceptibility 2 rs10490924 and Complement Factor H Y402H (P for trend = 4.2x10(-7)).